Do analysts rate ASLN or ENVB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Enveric Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ASLN or ENVB more profitable?

Enveric Biosciences' return on equity of -220.97% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% Enveric Biosciences N/A -220.97% -177.47%

Is ASLN or EGRX more profitable?

Eagle Pharmaceuticals' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% Eagle Pharmaceuticals N/A N/A N/A

Do analysts rate MBIO or ASLN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mustang Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is MBIO or ASLN more profitable?

Mustang Bio's return on equity of -35.38% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mustang Bio N/A -35.38% -16.36% ASLAN Pharmaceuticals N/A -8,454.87% -121.60%

Do analysts prefer ASLN or ALP?

Portage Biotech has a consensus price target of $2.00, suggesting a potential upside of 929.87%. Given Portage Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Portage Biotech is more favorable than ASLAN Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Portage Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ASLN or ALP more profitable?

Portage Biotech's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% Portage Biotech N/A N/A N/A

Do analysts prefer ASLN or ENTO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ASLAN Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ASLN or ENTO more profitable?

Entero Therapeutics' return on equity of -461.02% beat ASLAN Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ASLAN Pharmaceuticals N/A -8,454.87% -121.60% Entero Therapeutics N/A -461.02% -14.72%

ASLAN Pharmaceuticals (ASLN) Competitors

$0.60 0.00 (0.00%)

As of 08/3/2026

Compare

ASLN vs. ENVB, EGRX, MBIO, ALP, and ENTO

Should you buy ASLAN Pharmaceuticals stock or one of its competitors? MarketBeat compares ASLAN Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ASLAN Pharmaceuticals include Enveric Biosciences (ENVB), Eagle Pharmaceuticals (EGRX), Mustang Bio (MBIO), Portage Biotech (ALP), and Entero Therapeutics (ENTO).

How does ASLAN Pharmaceuticals compare to Enveric Biosciences?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Enveric Biosciences' return on equity of -220.97% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Enveric Biosciences	N/A	-220.97%	-177.47%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Enveric Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Enveric Biosciences has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Enveric Biosciences is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
Enveric Biosciences	N/A	N/A	-$8.77M	-$23.54	N/A

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

In the previous week, Enveric Biosciences' average media sentiment score of 0.80 beat ASLAN Pharmaceuticals' score of 0.00 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
Enveric Biosciences	Positive

Summary

ASLAN Pharmaceuticals beats Enveric Biosciences on 7 of the 11 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Eagle Pharmaceuticals?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Eagle Pharmaceuticals has higher revenue and earnings than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
Eagle Pharmaceuticals	$257.55M	0.02	$35.64M	$1.18	0.31

58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Eagle Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
Eagle Pharmaceuticals	Neutral

Eagle Pharmaceuticals' return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Eagle Pharmaceuticals	N/A	N/A	N/A

ASLAN Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

Summary

Eagle Pharmaceuticals beats ASLAN Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Mustang Bio?

Mustang Bio (NASDAQ:MBIO) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Mustang Bio's average media sentiment score of 0.00 equaled ASLAN Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Mustang Bio	Neutral
ASLAN Pharmaceuticals	Neutral

Mustang Bio's return on equity of -35.38% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mustang Bio	N/A	-35.38%	-16.36%
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mustang Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Mustang Bio has higher earnings, but lower revenue than ASLAN Pharmaceuticals. Mustang Bio is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mustang Bio	N/A	N/A	-$1.92M	-$0.48	N/A
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A

Mustang Bio has a beta of 2.06, meaning that its share price is 106% more volatile than the broader market. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market.

10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 4.0% of Mustang Bio shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Mustang Bio beats ASLAN Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Portage Biotech?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Portage Biotech (NASDAQ:ALP) are related small-cap companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, Portage Biotech had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for Portage Biotech and 0 mentions for ASLAN Pharmaceuticals. ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Portage Biotech'saverage media sentiment score.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
Portage Biotech	Neutral

Portage Biotech has lower revenue, but higher earnings than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
Portage Biotech	$100K	45.58	-$38.63M	-$8.18	N/A

Portage Biotech's return on equity of 0.00% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Portage Biotech	N/A	N/A	N/A

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Portage Biotech has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.4% of Portage Biotech shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Portage Biotech has a consensus price target of $2.00, suggesting a potential upside of 929.87%. Given Portage Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Portage Biotech is more favorable than ASLAN Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Portage Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Portage Biotech beats ASLAN Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does ASLAN Pharmaceuticals compare to Entero Therapeutics?

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Entero Therapeutics (NASDAQ:ENTO) are related small-cap companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ASLAN Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ASLAN Pharmaceuticals' average media sentiment score of 0.00 equaled Entero Therapeutics'average media sentiment score.

Company	Overall Sentiment
ASLAN Pharmaceuticals	Neutral
Entero Therapeutics	Neutral

58.8% of ASLAN Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Entero Therapeutics' return on equity of -461.02% beat ASLAN Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ASLAN Pharmaceuticals	N/A	-8,454.87%	-121.60%
Entero Therapeutics	N/A	-461.02%	-14.72%

ASLAN Pharmaceuticals has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

Entero Therapeutics has lower revenue, but higher earnings than ASLAN Pharmaceuticals. Entero Therapeutics is trading at a lower price-to-earnings ratio than ASLAN Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ASLAN Pharmaceuticals	$12M	0.10	-$44.22M	-$21.92	N/A
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A

Summary

ASLAN Pharmaceuticals and Entero Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get ASLAN Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ASLN vs. The Competition

Export

Metric	ASLAN Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.23M	$11.49B	$6.83B	$12.76B
Dividend Yield	N/A	2.73%	2.59%	10.01%
P/E Ratio	-0.03	791.61	279.15	25.53
Price / Sales	0.10	735.50	592.00	94.29
Price / Cash	N/A	71.54	72.11	49.39
Price / Book	-0.09	10.83	12.95	6.11
Net Income	-$44.22M	$2.81B	$3.48B	$347.58M
7 Day Performance	N/A	2.70%	3.40%	4.91%
1 Month Performance	N/A	-3.13%	-2.79%	-2.06%
1 Year Performance	N/A	190.97%	73.07%	21.03%

ASLAN Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ASLN ASLAN Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$1.23M	$12M	N/A	30
ENVB Enveric Biosciences	0.7507 of 5 stars	$1.33 flat	N/A	-87.8%	$4.90M	N/A	N/A	20
EGRX Eagle Pharmaceuticals	N/A	$0.37 flat	N/A	N/A	$4.81M	$257.55M	0.31	100	Upcoming Earnings
MBIO Mustang Bio	0.6787 of 5 stars	$0.58 -8.1%	N/A	-60.7%	$4.78M	N/A	N/A	100	Gap Down High Trading Volume
ALP Portage Biotech	1.3717 of 5 stars	$0.19 -7.4%	$2.00 +966.1%	N/A	$4.75M	$100K	N/A	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ASLN) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ASLAN Pharmaceuticals (ASLN) Competitors

ASLN vs. ENVB, EGRX, MBIO, ALP, and ENTO

How does ASLAN Pharmaceuticals compare to Enveric Biosciences?

Summary

How does ASLAN Pharmaceuticals compare to Eagle Pharmaceuticals?

Summary

How does ASLAN Pharmaceuticals compare to Mustang Bio?

Summary

How does ASLAN Pharmaceuticals compare to Portage Biotech?

Summary

How does ASLAN Pharmaceuticals compare to Entero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN vs. The Competition

ASLAN Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ASLAN Pharmaceuticals (ASLN) Competitors

ASLN vs. ENVB, EGRX, MBIO, ALP, and ENTO

How does ASLAN Pharmaceuticals compare to Enveric Biosciences?

Is ASLN or ENVB more profitable?

Do analysts rate ASLN or ENVB?

Do insiders and institutionals have more ownership in ASLN or ENVB?

Which has higher valuation and earnings, ASLN or ENVB?

Which has more risk and volatility, ASLN or ENVB?

Does the media favor ASLN or ENVB?

Summary

How does ASLAN Pharmaceuticals compare to Eagle Pharmaceuticals?

Which has preferable valuation and earnings, ASLN or EGRX?

Do insiders and institutionals have more ownership in ASLN or EGRX?

Does the media refer more to ASLN or EGRX?

Is ASLN or EGRX more profitable?

Which has more risk and volatility, ASLN or EGRX?

Summary

How does ASLAN Pharmaceuticals compare to Mustang Bio?

Does the media refer more to MBIO or ASLN?

Is MBIO or ASLN more profitable?

Do analysts rate MBIO or ASLN?

Which has stronger valuation & earnings, MBIO or ASLN?

Which has more risk & volatility, MBIO or ASLN?

Do institutionals and insiders hold more shares of MBIO or ASLN?

Summary

How does ASLAN Pharmaceuticals compare to Portage Biotech?

Does the media refer more to ASLN or ALP?

Which has higher earnings & valuation, ASLN or ALP?

Is ASLN or ALP more profitable?

Which has more risk & volatility, ASLN or ALP?

Do insiders and institutionals hold more shares of ASLN or ALP?

Do analysts prefer ASLN or ALP?

Summary

How does ASLAN Pharmaceuticals compare to Entero Therapeutics?

Do analysts prefer ASLN or ENTO?

Does the media prefer ASLN or ENTO?

Do insiders and institutionals have more ownership in ASLN or ENTO?

Is ASLN or ENTO more profitable?

Which has more volatility and risk, ASLN or ENTO?

Which has better valuation & earnings, ASLN or ENTO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ASLN vs. The Competition

ASLAN Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools